OncoZenge AB (8LY) Price & Analysis

0 Followers

8LY Stock Chart & Stats

€0.59

-€0.02(-7.82%)

At close: Jan 08 4:00 PM EST

€0.59

-€0.02(-7.82%)

Day’s Range― - ―

52-Week Range€0.45 - €0.75

Previous CloseN/A

Volume0.00

Average Volume (3M)0.00

Market Cap

€8.70M

Enterprise Value€79.68

Total Cash (Recent Filing)€935.00K

Total Debt (Recent Filing)€7.50M

Price to Earnings (P/E)―

Beta0.49

Next Earnings

Aug 27, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-1.74

Shares Outstanding14,048,068

10 Day Avg. Volume0

30 Day Avg. Volume0

Financial Highlights & Ratios

PEG Ratio-0.07

Price to Book (P/B)-139.70

Price to Sales (P/S)30.78

P/FCF Ratio-6.28

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-0.09

Revenue Forecast (FY)€924.04K

Bulls Say, Bears Say

Bulls Say

Multi-path Commercialisation ModelThe company explicitly pursues direct commercialization and out‑licensing/collaboration routes for BupiZenge™, providing durable revenue optionality. Multiple monetization paths reduce single-channel dependency and allow partner-funded scale or retained upside from direct sales.

Focus On Supportive Cancer CareBupiZenge targets oral mucositis pain, a recurring adverse effect of chemotherapy/radiotherapy. This represents a structurally persistent clinical need across oncology populations, supporting repeatable demand and long‑term addressable market if safety and efficacy are validated.

Positive Product-level Gross ProfitPositive TTM gross profit indicates that unit economics at the product level can be viable. If sales scale and operating costs are controlled, positive gross margins provide a foundation to improve operating margins and achieve sustainable profitability over time.

Bears Say

Persistent Heavy Cash BurnLarge negative operating cash flow and ongoing free cash outflows mean the company must continually raise external capital. That increases dilution or leverage, constrains multi‑period planning, and limits ability to invest steadily in commercialization and regulatory execution.

Extremely High Leverage On Thin EquityDebt of ~7.5M versus minimal equity creates acute leverage and refinancing risk. This materially reduces financial flexibility, increases interest and covenant vulnerability, and can deter partners or limit investment during critical commercial scaling phases.

Minimal And Contracting Revenue BaseA tiny revenue base combined with a ~96% decline vs prior period undermines the company's ability to cover fixed costs and validate market traction. Sustained low sales prolong dependency on external funding and raise structural doubts about scalability.

OncoZenge AB News

OncoZenge’s BupiZenge Heads Into Phase III: What This Pain Study Means for Investors

OncoZenge AB ($DE:8LY) announced an update on their ongoing clinical study. The phase III trial “A Randomized, Open-label,...

1M ago

8LY

8LY FAQ

What was OncoZenge AB’s price range in the past 12 months?

OncoZenge AB lowest stock price was €0.45 and its highest was €0.75 in the past 12 months.

What is OncoZenge AB’s market cap?

OncoZenge AB’s market cap is €8.70M.

When is OncoZenge AB’s upcoming earnings report date?

OncoZenge AB’s upcoming earnings report date is Aug 27, 2026 which is in 25 days.

How were OncoZenge AB’s earnings last quarter?

OncoZenge AB released its earnings results on May 20, 2026. The company reported -€0.049 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.

Is OncoZenge AB overvalued?

According to Wall Street analysts OncoZenge AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does OncoZenge AB pay dividends?

OncoZenge AB does not currently pay dividends.

What is OncoZenge AB’s EPS estimate?

OncoZenge AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does OncoZenge AB have?

OncoZenge AB has 14,048,068 shares outstanding.

What happened to OncoZenge AB’s price movement after its last earnings report?

OncoZenge AB reported an EPS of -€0.049 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 3.407%.

Which hedge fund is a major shareholder of OncoZenge AB?

Currently, no hedge funds are holding shares in DE:8LY

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

OncoZenge AB

OncoZenge AB (publ) operates as a pharmaceutical company with a focus on developing medical solutions that offer supportive care for cancer patients. A significant product in its pipeline is BupiZenge, which has successfully completed Phase 2 clinical trials for the management of oral mucositis. This company was established in 2020 and conducts its operations from its headquarters in Bromma, Sweden. Notably, OncoZenge AB (publ) is a subsidiary entity of Moberg Pharma AB (publ).